LEUKEMIA, MYELOID, ACUTE

This phase 2 trial is testing a new treatment called Orca-T for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Orca-T is a personalized cell therapy made from a donor's blood that includes stem cells and immune cells. The goal is to see if it can impr…

This study tests whether adding the experimental drug bleximenib to standard treatment (venetoclax and azacitidine) helps people with a specific genetic subtype of acute myeloid leukemia (AML) achieve remission and live longer. The trial enrolls 600 adults aged 18 and older who h…

This early-stage trial is testing an experimental drug called JNJ-90189892 in about 155 people with acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS) that have come back or not responded to treatment. The study has several parts: first, finding a safe dose of JNJ-90…

This early-stage trial is testing a new drug called ziftomenib combined with standard chemotherapy or another targeted drug for people with relapsed or treatment-resistant acute myeloid leukemia (AML) that has specific genetic changes. The main goal is to see if these combination…

This early-stage trial tests a new treatment for adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize and attack…

This study tests a new oral drug called enzomenib (DSP-5336) in people with acute leukemia and certain other blood cancers that have not responded to standard treatments. The trial has two phases: first, finding the safest dose, and then checking how well it works alone or combin…

This early-phase trial tests an experimental oral drug called BH-30236 in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The study first tests BH-30236 alone, then in combination with another drug, venetoclax. About 17…

This study is testing whether a combination of two drugs—azacitidine (given as a shot) and chidamide (taken as a pill)—can safely prevent high-risk acute myeloid leukemia from coming back after a stem cell transplant. About 20 adults aged 18 to 60 will receive six cycles of azaci…

This phase 2 trial is testing a combination of three drugs—venetoclax, chidamide, and azacitidine—in 30 adults with acute myeloid leukemia that has relapsed or not responded to prior treatment. The goal is to see if this combo can safely improve remission rates and survival. Part…

This study tests a combination of two drugs, DFP-10917 and venetoclax, in 39 adults with acute myeloid leukemia that has relapsed or not responded to prior treatments. DFP-10917 is given as a continuous 14-day IV infusion, while venetoclax is taken orally for 10-14 days each cycl…

This study is collecting genetic samples from 50 adults with newly diagnosed acute myeloid leukemia (AML) who are starting treatment with azacitidine and venetoclax. Researchers want to see if certain genetic variations are linked to severe side effects or how well the drugs work…